Cancer News

The latest in diagnostics and treatment

As a practice dedicated to the constant exploration of effective treatment for cancer, VCI aims to be your source for news on the latest breakthroughs. Please keep this page as a bookmark and check back regularly. Because one of the most important aspects of fighting cancer is knowing all you can.

World Cancer News

Keytruda Trail Results Suggest Change in Management of Squamous Non-Small Cell Lung Cancer (06/22/2018)

An interim analysis of the phase III KEYNOTE-407 trial evaluated combined chemotherapy and immunotherapy showed a more than four-month longer median overall survival for metastatic squamous non–small-cell lung cancer (NSCLC) patients who received keytruda (pembrolizumab) plus traditional chemotherapy compared with those who received placebo plus chemotherapy. About Lung Cancer Lung cancer remains the leading cause …

Continue reading "Keytruda Trail Results Suggest Change in Management of Squamous Non-Small Cell Lung Cancer"

U.S. FDA Agrees to Review Talazoparib for Advanced and Triple Negative Breast Cancer for Treatment of Patients with an Inherited BRCA Mutation (06/21/2018)

The U.S. Food and Drug Administration accepted for filing and granted Priority Review designation for Pfizer’s New Drug Application for talazoparib. The submission is based on results from the EMBRACA trial, which compared talazoparib to chemotherapy in patients with inherited BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. About Talazoparib Talazoparib is an investigational anti-cancer …

Continue reading "U.S. FDA Agrees to Review Talazoparib for Advanced and Triple Negative Breast Cancer for Treatment of Patients with an Inherited BRCA Mutation"

mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer (06/19/2018)

The results of a recently presented clinical study at the American Society of Clinical Oncology meetings last week suggest that more aggressive chemotherapy treatment improves outcomes compared to single agent Gemzar (gemcitabine) chemotherapy which has been a standard treatment for over a decade. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of …

Continue reading "mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer"

Newly Diagnosed with Ovarian Cancer? 10 Must Read Tips to be an Empowered Patient (06/18/2018)

For many years ovarian cancer has been referred to as “the silent killer” due to its vague, ignored, or misdiagnosed symp­toms. Because of this and the lack of ear­ly-detection tools, ovarian cancer often goes undiagnosed until it has reached the later stages, when it is harder to treat. Information and support and are key to …

Continue reading "Newly Diagnosed with Ovarian Cancer? 10 Must Read Tips to be an Empowered Patient"

FDA Approves Merck’s Keytruda® for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (06/18/2018)

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1.  Keytruda is the first Anti-PD-1 therapy approved for patients with advanced cervical cancer and the first indication for Keytruda in a gynecologic …

Continue reading "FDA Approves Merck’s Keytruda® for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1"

University of Colorado Study Suggests new Combination Treatment for Head and Neck Cancer (06/14/2018)

The five-year survival rate for locally-advanced head and neck cancer is only 46 percent, even with treatments including surgery, radiation, chemotherapy and/or genetically targeted treatments such as cetuximab. Often, the problem is that while treatments initially work, cancer evolves to resist treatment. “The question has been how do cancers resist these treatments,” says Sana Karam, MD, PhD, …

Continue reading "University of Colorado Study Suggests new Combination Treatment for Head and Neck Cancer"

Vicinium Represents New Treatment Option for Non- Muscle Invasive Badder Cancer (06/06/2018)

Today three-month data from the ongoing Phase 3 VISTA Trial of Vicinium™ for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-Guérin (BCG) were released. Overall 43% of patients achieved a complete response and Vicinium appears to represent an emerging treatment option. About Vicinium™ Vicinium™, …

Continue reading "Vicinium Represents New Treatment Option for Non- Muscle Invasive Badder Cancer"

Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations (06/05/2018)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy. The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a medicine …

Continue reading "Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations"

Loxo-292 Promising for Lung and Other “RET Fusion” Cancers (06/04/2018)

On Saturday, Loxo Oncology in a presentation at the American Society of Clinical Oncology annual meeting in Chicago unveiled clinical trial data for LOXO-292, a novel precision cancer medicine targeting tumors containing a mutated protein known as RET. About LOXO-202 LOXO-292 is an oral precision cancer medicine that is designed to target cancers with genomic …

Continue reading "Loxo-292 Promising for Lung and Other “RET Fusion” Cancers"

FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma (05/31/2018)

The US Food and Drug Administration (FDA) has granted approval to Calquence (acalabrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Calquence is a highly-selective, potent Bruton tyrosine kinase (BTK) inhibitor being evaluated for the treatment of multiple B-cell cancers. About mantle cell lymphoma Mantle …

Continue reading "FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma"